Amgen Inc. $AMGN Shares Sold by Vivaldi Capital Management LP

Vivaldi Capital Management LP reduced its position in Amgen Inc. (NASDAQ:AMGN) by 4.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 46,681 shares of the medical research company’s stock after selling 2,315 shares during the period. Amgen accounts for approximately 2.3% of Vivaldi Capital Management LP’s holdings, making the stock its 11th biggest holding. Vivaldi Capital Management LP’s holdings in Amgen were worth $16,425,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Entropy Technologies LP bought a new position in Amgen during the 1st quarter worth approximately $3,223,000. Sustainable Insight Capital Management LLC grew its position in shares of Amgen by 62.1% in the 1st quarter. Sustainable Insight Capital Management LLC now owns 1,357 shares of the medical research company’s stock worth $477,000 after acquiring an additional 520 shares in the last quarter. Bridgewater Advisors Inc. increased its holdings in shares of Amgen by 2.3% in the 1st quarter. Bridgewater Advisors Inc. now owns 2,545 shares of the medical research company’s stock valued at $852,000 after acquiring an additional 57 shares during the last quarter. Bollard Group LLC increased its holdings in shares of Amgen by 3.2% in the 1st quarter. Bollard Group LLC now owns 4,087 shares of the medical research company’s stock valued at $1,438,000 after acquiring an additional 126 shares during the last quarter. Finally, Hilltop Holdings Inc. raised its position in shares of Amgen by 77.2% during the 1st quarter. Hilltop Holdings Inc. now owns 6,089 shares of the medical research company’s stock valued at $2,142,000 after acquiring an additional 2,653 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AMGN. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Finally, Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $356.62.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.2%

Shares of NASDAQ AMGN opened at $376.04 on Friday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The company has a market cap of $202.95 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.76 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock’s 50 day simple moving average is $351.28 and its 200 day simple moving average is $351.80.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the prior year, the business earned $4.90 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts expect that Amgen Inc. will post 22.31 EPS for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.